ClinicalTrials.gov
public full text
Public Domain
Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly
A randomized controlled pilot trial with the aim of identifying the dose of liposomal amphotericin B associated with the highest cure rate in Cutaneous Leishmaniasis (CL). We selected 28 patients of both sexes, aged 60 years or older, diagnosed with CL and confirmed by detection of L. braziliensis DNA. The groups were treated with different total doses of medication: G1: 12 mg/kg; G2: 18mg/kg; G3: 24 mg/kg. Clinical and laboratory evaluations were carried out during the period of 180 days (D0, D15, D30, D60, D120, D150 and D180).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly#888142
- Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar#853320
- Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World#1046219
- Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis#851564
- Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis#1058603
Record · ID 1096180
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive